Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00776022 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00776022: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00776022 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00776022, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fed condition
Interventions
- DRUG Cetirizine Hydrochloride 10 mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-06 |
| Phase | NA |
What the finished NCT00776022 record still lists
NCT00776022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Cetirizine Hydrochloride 10 mg tablet is the first listed.
NCT00776022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00776022 about?
NCT00776022 is a clinical study titled "Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions". An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pf...
What is the current status of trial NCT00776022?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2005-04. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00776022?
The interventions under investigation include: Cetirizine Hydrochloride 10 mg tablet (DRUG).
Who is sponsoring clinical trial NCT00776022?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00776022's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia